Increment in Dietary Potassium Predicts Weight Loss in the Treatment of the Metabolic Syndrome.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
02 Jun 2019
Historique:
received: 29 04 2019
revised: 27 05 2019
accepted: 30 05 2019
entrez: 5 6 2019
pubmed: 5 6 2019
medline: 7 1 2020
Statut: epublish

Résumé

In the treatment of obesity/metabolic syndrome, dietary measures traditionally focus on reducing carbohydrate/fat-related caloric intake. The possibility that changes in potassium consumption may be related to the achieved weight loss has not been previously explored. Sixty-eight participants, with a mean age of 51.6 ± 11.0 years (F/M-30/38), who fulfilled the ATPIII criteria for the metabolic syndrome (MS) were enrolled into a 1-year intensive multidisciplinary program. Nutritional recommendation consisted of a moderate low calorie/high protein Mediterranean diet. Baseline assessment included clinical and biochemical profiling, and body composition. Nutritional components were registered over 7 days before and at the end of 1 year of treatment. Mean baseline body mass index (BMI) was 35 ± 4 kg/m², which declined by 9.4 ± 0.1% after one year of combined intervention. Linear stepwise regression analysis revealed that 45% of the predicted variance of the % decline in BMI was related to increased consumption of dietary potassium (β = -0.865) and caproic acid (β = -0.423) and reduction in the consumption of dietary vitamin B6 (β = 0.542), calcium (β = 0.335), total carbohydrates (β = 0.239) and total caloric intake (β = 0.238; An increase in dietary potassium consumption is a previously unrecognized predictor of the achieved reduction in BMI in a weight-loss-oriented multidisciplinary intervention in obesity/MS. Prospective trials are underway to confirm this post-hoc finding.

Sections du résumé

BACKGROUND BACKGROUND
In the treatment of obesity/metabolic syndrome, dietary measures traditionally focus on reducing carbohydrate/fat-related caloric intake. The possibility that changes in potassium consumption may be related to the achieved weight loss has not been previously explored.
METHODS METHODS
Sixty-eight participants, with a mean age of 51.6 ± 11.0 years (F/M-30/38), who fulfilled the ATPIII criteria for the metabolic syndrome (MS) were enrolled into a 1-year intensive multidisciplinary program. Nutritional recommendation consisted of a moderate low calorie/high protein Mediterranean diet. Baseline assessment included clinical and biochemical profiling, and body composition. Nutritional components were registered over 7 days before and at the end of 1 year of treatment.
RESULTS RESULTS
Mean baseline body mass index (BMI) was 35 ± 4 kg/m², which declined by 9.4 ± 0.1% after one year of combined intervention. Linear stepwise regression analysis revealed that 45% of the predicted variance of the % decline in BMI was related to increased consumption of dietary potassium (β = -0.865) and caproic acid (β = -0.423) and reduction in the consumption of dietary vitamin B6 (β = 0.542), calcium (β = 0.335), total carbohydrates (β = 0.239) and total caloric intake (β = 0.238;
CONCLUSION CONCLUSIONS
An increase in dietary potassium consumption is a previously unrecognized predictor of the achieved reduction in BMI in a weight-loss-oriented multidisciplinary intervention in obesity/MS. Prospective trials are underway to confirm this post-hoc finding.

Identifiants

pubmed: 31159504
pii: nu11061256
doi: 10.3390/nu11061256
pmc: PMC6627830
pii:
doi:

Substances chimiques

Potassium, Dietary 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Sagol grant for the SagolCenter for the Metabolic Syndrome research
ID : None

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Am J Clin Nutr. 2005 May;81(5):983-9
pubmed: 15883419
J Nutr. 2009 Jun;139(6):1150-6
pubmed: 19357215
Arch Intern Med. 2010 Jan 25;170(2):126-35
pubmed: 20101007
J Hypertens. 2011 Sep;29(9):1719-30
pubmed: 21799445
Diabetologia. 2012 May;55(5):1295-303
pubmed: 22322920
Am J Clin Nutr. 2012 Sep;96(3):647-57
pubmed: 22854410
PLoS One. 2013;8(1):e55106
pubmed: 23372822
Semin Nephrol. 2013 May;33(3):248-56
pubmed: 23953802
Atherosclerosis. 2013 Sep;230(1):80-5
pubmed: 23958257
Am J Clin Nutr. 2014 May;99(5):992-8
pubmed: 24552753
Br J Nutr. 2015 Apr 28;113(8):1308-18
pubmed: 25782331
J Clin Hypertens (Greenwich). 2016 Jan;18(1):19-24
pubmed: 26408073
Nutrients. 2016 Mar 25;8(4):183
pubmed: 27023597
Diabetes Metab Res Rev. 2017 Feb;33(2):
pubmed: 27393712
Exp Clin Endocrinol Diabetes. 2017 Sep;125(8):571-576
pubmed: 28926857
Obesity (Silver Spring). 2018 Feb;26(2):442-450
pubmed: 29318759
JAMA. 1997 May 28;277(20):1624-32
pubmed: 9168293

Auteurs

Brurya Tal (B)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. bruryat@tlvmc.gov.il.

Jessica Sack (J)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. jessicasack8@gmail.com.

Marianna Yaron (M)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. yaron5@orange.net.il.

Gabi Shefer (G)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. gabish@tlvmc.gov.il.

Assaf Buch (A)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. buchasaf@gmail.com.

Limor Ben Haim (L)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. lbenhaim1@gmail.com.

Yonit Marcus (Y)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. yonitm@tlvmc.gov.il.

Galina Shenkerman (G)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. galina.shenkerman@gmail.com.

Yael Sofer (Y)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. yaelso@tlvmc.gov.il.

Lili Shefer (L)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. gabi.shefer@gmail.com.

Miri Margaliot (M)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. mirim@tlvmc.gov.il.

Naftali Stern (N)

Thhe Sagol Center for Epigenetics of Aging and Metabolism, the Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6423906 Tel Aviv, Israel. naftalis@tlvmc.gov.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH